Pneumotox » Drug » Erlotinib » I.b

Erlotinib

I.b Pneumonitis (ILD)

Incidence estimates 4,5% in Japan (PMID 22610257) as opposed to 0.4% in the West (PMID 18438878). Possible explanations for the discrepancy at PMID 27004571

Last update : 05/01/2020

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

More detailed checklist

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

Erlotinib

I.b Pneumonitis (ILD)

Publications